(BAX) Baxter International - Ratings and Ratios
IV Solutions, Infusion Devices, Injectable Drugs, Surgical Sealants, Dialysis Equipment
BAX EPS (Earnings per Share)
BAX Revenue
Description: BAX Baxter International October 30, 2025
Baxter International Inc. (NYSE:BAX) is a diversified healthcare-product company headquartered in Deerfield, Illinois. It serves U.S. and global markets through three operating segments-Medical Products and Therapies, Healthcare Systems and Technologies, and Pharmaceuticals-offering a broad array of items such as sterile IV solutions, infusion devices, parenteral nutrition, generic injectables, surgical hemostats, smart-bed systems, patient-monitoring tools, and respiratory health equipment. Sales channels include a direct force, independent distributors, drug wholesalers, and specialty pharmacies, and the firm operates in North America, Europe, Asia, the Middle East, Africa, and Latin America.
Key recent metrics underscore Baxter’s scale and financial health: FY 2023 revenue reached approximately $12.5 billion, with operating cash flow of about $2.2 billion and an adjusted EPS of $4.55. The company’s acquisition of Hill-Rom in 2021 expanded its smart-hospital-bed portfolio, positioning it to capture growth in the hospital-capital-expenditure cycle, which the American Hospital Association estimates will rise 3-4 % annually through 2027. Additionally, the home-infusion market-driven by an aging population and increasing preference for outpatient care-is projected to grow at a CAGR of roughly 6 % over the next five years, a segment where Baxter’s specialty injectable and compounding services are well-aligned.
For a deeper quantitative assessment of BAX’s valuation metrics and peer comparisons, the ValueRay platform offers a concise dashboard worth reviewing.
BAX Stock Overview
| Market Cap in USD | 11,824m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1981-10-27 |
BAX Stock Ratings
| Growth Rating | -85.2% |
| Fundamental | 33.7% |
| Dividend Rating | 27.7% |
| Return 12m vs S&P 500 | -53.9% |
| Analyst Rating | 3.44 of 5 |
BAX Dividends
| Dividend Yield 12m | 3.55% |
| Yield on Cost 5y | 0.96% |
| Annual Growth 5y | 1.76% |
| Payout Consistency | 55.9% |
| Payout Ratio | 30.8% |
BAX Growth Ratios
| Growth Correlation 3m | -51.4% |
| Growth Correlation 12m | -75.6% |
| Growth Correlation 5y | -93.3% |
| CAGR 5y | -25.82% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.41 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.80 |
| Sharpe Ratio 12m | -0.68 |
| Alpha | -58.01 |
| Beta | 0.577 |
| Volatility | 33.91% |
| Current Volume | 24012.8k |
| Average Volume 20d | 5515.4k |
| Stop Loss | 18.4 (-4%) |
| Signal | -1.01 |
Piotroski VR‑10 (Strict, 0-10) 2.5
| Net Income (-155.0m TTM) > 0 and > 6% of Revenue (6% = 653.2m TTM) |
| FCFTA 0.02 (>2.0%) and ΔFCFTA -0.36pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 35.00% (prev 21.10%; Δ 13.90pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.04 (>3.0%) and CFO 765.0m > Net Income -155.0m (YES >=105%, WARN >=100%) |
| Net Debt (8.04b) to EBITDA (910.0m) ratio: 8.83 <= 3.0 (WARN <= 3.5) |
| Current Ratio 2.30 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (514.0m) change vs 12m ago 0.78% (target <= -2.0% for YES) |
| Gross Margin 36.59% (prev 38.74%; Δ -2.14pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 45.98% (prev 44.34%; Δ 1.63pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 0.09 (EBITDA TTM 910.0m / Interest Expense TTM 354.0m) >= 6 (WARN >= 3) |
Altman Z'' 4.42
| (A) 0.18 = (Total Current Assets 6.75b - Total Current Liabilities 2.94b) / Total Assets 21.05b |
| (B) 0.71 = Retained Earnings (Balance) 14.97b / Total Assets 21.05b |
| (C) 0.00 = EBIT TTM 32.0m / Avg Total Assets 23.68b |
| (D) 0.87 = Book Value of Equity 11.91b / Total Liabilities 13.75b |
| Total Rating: 4.42 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 33.67
| 1. Piotroski 2.50pt = -2.50 |
| 2. FCF Yield 1.68% = 0.84 |
| 3. FCF Margin 3.06% = 0.76 |
| 4. Debt/Equity 1.33 = 1.68 |
| 5. Debt/Ebitda 8.83 = -2.50 |
| 6. ROIC - WACC (= -4.62)% = -5.77 |
| 7. RoE -2.12% = -0.35 |
| 8. Rev. Trend -71.07% = -5.33 |
| 9. EPS Trend -63.13% = -3.16 |
What is the price of BAX shares?
Over the past week, the price has changed by -16.66%, over one month by -14.39%, over three months by -31.21% and over the past year by -45.35%.
Is Baxter International a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BAX is around 13.79 USD . This means that BAX is currently overvalued and has a potential downside of -28.03%.
Is BAX a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the BAX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 28 | 46.1% |
| Analysts Target Price | 28 | 46.1% |
| ValueRay Target Price | 14.9 | -22.4% |
BAX Fundamental Data Overview October 28, 2025
P/E Forward = 9.2937
P/S = 1.086
P/B = 1.63
P/EG = 1.9974
Beta = 0.577
Revenue TTM = 10.89b USD
EBIT TTM = 32.0m USD
EBITDA TTM = 910.0m USD
Long Term Debt = 9.49b USD (from longTermDebt, last quarter)
Short Term Debt = 8.00m USD (from shortTermDebt, last quarter)
Debt = 9.72b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 8.04b USD (from netDebt column, last quarter)
Enterprise Value = 19.86b USD (11.82b + Debt 9.72b - CCE 1.69b)
Interest Coverage Ratio = 0.09 (Ebit TTM 32.0m / Interest Expense TTM 354.0m)
FCF Yield = 1.68% (FCF TTM 333.0m / Enterprise Value 19.86b)
FCF Margin = 3.06% (FCF TTM 333.0m / Revenue TTM 10.89b)
Net Margin = -1.42% (Net Income TTM -155.0m / Revenue TTM 10.89b)
Gross Margin = 36.59% ((Revenue TTM 10.89b - Cost of Revenue TTM 6.90b) / Revenue TTM)
Gross Margin QoQ = 40.25% (prev 32.80%)
Tobins Q-Ratio = 0.94 (Enterprise Value 19.86b / Total Assets 21.05b)
Interest Expense / Debt = 0.74% (Interest Expense 72.0m / Debt 9.72b)
Taxrate = 8.27% (11.0m / 133.0m)
NOPAT = 29.4m (EBIT 32.0m * (1 - 8.27%))
Current Ratio = 2.30 (Total Current Assets 6.75b / Total Current Liabilities 2.94b)
Debt / Equity = 1.33 (Debt 9.72b / totalStockholderEquity, last quarter 7.32b)
Debt / EBITDA = 8.83 (Net Debt 8.04b / EBITDA 910.0m)
Debt / FCF = 24.14 (Net Debt 8.04b / FCF TTM 333.0m)
Total Stockholder Equity = 7.31b (last 4 quarters mean from totalStockholderEquity)
RoA = -0.74% (Net Income -155.0m / Total Assets 21.05b)
RoE = -2.12% (Net Income TTM -155.0m / Total Stockholder Equity 7.31b)
RoCE = 0.19% (EBIT 32.0m / Capital Employed (Equity 7.31b + L.T.Debt 9.49b))
RoIC = 0.16% (NOPAT 29.4m / Invested Capital 18.72b)
WACC = 4.77% (E(11.82b)/V(21.55b) * Re(8.14%) + D(9.72b)/V(21.55b) * Rd(0.74%) * (1-Tc(0.08)))
Discount Rate = 8.14% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 0.69%
[DCF Debug] Terminal Value 70.04% ; FCFE base≈404.2m ; Y1≈265.4m ; Y5≈121.4m
Fair Price DCF = 4.57 (DCF Value 2.35b / Shares Outstanding 513.6m; 5y FCF grow -40.0% → 3.0% )
EPS Correlation: -63.13 | EPS CAGR: -63.44% | SUE: -4.0 | # QB: 0
Revenue Correlation: -71.07 | Revenue CAGR: -8.70% | SUE: -0.01 | # QB: 0
Additional Sources for BAX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle